IKS Inventurus Knowledge Solutions Q1 FY26 results (Apr–Jun 2025) and concall
IKS Health reported a strong Q1 FY26 with robust revenue growth of 16% YoY and significant margin expansion, driven by the successful integration of AQuity and operational efficiencies. The company continues to advance its AI-native platform, secure key client wins, and make progress on strategic outcome-oriented deals like Palomar and Western Washington. Despite a material revenue drag from intentional client pruning, profitability metrics saw substantial improvement, and net debt continued to reduce.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 240 | 241 | 290 | 319 |
| EBITDA | 116 | 103 | 129 | 150 |
| Net profit | 92 | 83 | 100 | 113 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
